Tuberculosis and Respiratory Diseases

  • 제77권6호
  • /
  • Pages.271-273
  • /
  • 2014
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

Systemic Nocardiosis Mimicking Disease Flare-up after Discontinuation of Gefitinib in a Patient with EGFR-Mutant Lung Cancer

  • Choi, Mihong (Department of Internal Medicine, Center for Diagnostic Oncology, National Cancer Center) ;
  • Lee, Youngjoo (Department of Internal Medicine, Center for Diagnostic Oncology, National Cancer Center) ;
  • Hwang, Sang Hyun (Department of Laboratory Medicine, Center for Diagnostic Oncology, National Cancer Center) ;
  • Lee, Jin Soo (Department of Internal Medicine, Center for Diagnostic Oncology, National Cancer Center)
  • 투고 : 2014.06.13
  • 심사 : 2014.09.03
  • 발행 : 2014.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Disease flare-up after discontinuing epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been considered as a critical issue in lung cancer patients who have experienced radiologic progression after showing initial durable response. This is a case of systemic nocardiosis that occurred after chronic steroid use for radionecrosis from stereotactic radiosurgery. It was initially thought as a disease flare-up after stopping EGFR-TKI.

키워드

참고문헌

  1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004;350: 2129-39. https://doi.org/10.1056/NEJMoa040938
  2. Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011;17:6298-303. https://doi.org/10.1158/1078-0432.CCR-11-1468
  3. Saubolle MA, Sussland D. Nocardiosis: review of clinical and laboratory experience. J Clin Microbiol 2003;41:4497-501. https://doi.org/10.1128/JCM.41.10.4497-4501.2003
  4. Ambrosioni J, Lew D, Garbino J. Nocardiosis: updated clinical review and experience at a tertiary center. Infection 2010;38: 89-97. https://doi.org/10.1007/s15010-009-9193-9
  5. Kano H, Kondziolka D, Zorro O, Lobato-Polo J, Flickinger JC, Lunsford LD. The results of resection after stereotactic radiosurgery for brain metastases. J Neurosurg 2009;111:825-31. https://doi.org/10.3171/2009.4.JNS09246
  6. Petrovich Z, Yu C, Giannotta SL, O'Day S, Apuzzo ML. Survival and pattern of failure in brain metastasis treated with stereotactic gamma knife radiosurgery. J Neurosurg 2002;97(5 Suppl): 499-506.